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Abstract 
Ion beams exhibit a finite and well defined range in matter together with an 
“inverted” depth-dose profile, the so-called Bragg peak. These favourable 
physical properties may enable superior tumour-dose conformality for high 
precision radiation therapy. On the other hand, they introduce the issue of 
sensitivity to range uncertainties in ion beam therapy. Although these 
uncertainties are typically taken into account when planning the treatment, 
correct delivery of the intended ion beam range has to be assured to prevent 
undesired underdosage of the tumour or overdosage of critical structures 
outside the target volume. Therefore, it is necessary to define dedicated 
Quality Assurance procedures to enable in-vivo range verification before or 
during therapeutic irradiation. For these purposes, Monte Carlo transport 
codes are very useful tools to support the development of novel imaging 
modalities for ion beam therapy. In the present work, we present calculations 
performed with the FLUKA Monte Carlo code and preliminary experimental 
studies. 
1 Introduction 
Ion beam therapy has no primary radiation emerging from the patient, in fact the energy deposited by 
a therapeutic ion beam increases in front of the tumor target and sharply decreases in the healthy 
behind the target, where no or small amount of dose is deposited. This “inverted” depth-dose profile, 
the so-called Bragg peak, represents a major advantage of ion beams over conventional external beam 
modalities for highly conformal dose delivery. On the other hand, the finite range of the beam in the 
patient needs to be accurately determined for correct dose deposition to the target volume. Therefore, 
in-vivo verification of the actual treatment delivery requires dedicated Quality Assurance (QA) and 
novel imaging techniques for in-vivo monitoring of the ion beam range and/or reliable indicators 
of the ion dose deposition. Dose calculations and optimization in particle treatment planning are 
tipically  computed on X-ray CT images, which represent the distribution of mean X-ray absorption 
coefficients relative to water. From X-ray CT data the particle ranges in tissue can be calculated only 
with about 1-3% range accuracy [1, 2], corresponding to few millimeters in some clinical cases. The 
main limiting factor is the translation of the Hounsfield units, as measured with a CT scanner, to water 
equivalent path length (WEPL). This translation, which is presently based on semiempirical 
calibration curves [2, 3], can cause differences between treatment planning and treatment delivery. 
One straightforward way to avoid this uncertainty and to improve the accuracy of the calculated 
particle ranges in tissue could be the use of ion radiography or tomography [4, 5]. This requires the 
usage of high energy primary particles for obtaining low dose transmitted planar (radiographic) or 
volumetric (tomographic) images of the patient for pre-treatment verification of the residual ion range. 
In addition, this method can allow obtaining information on the correct positioning of the patient 
without the use of external X-ray radiation. Besides, detection of the emerging secondary particles 
from the primary ion beam could be exploited for in-vivo verification of the treatment delivery 
simultaneously to the therapeutic irradiation. 
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2 Material and Methods 
In order to study the feasibility and optimal detection systems for new QA and imaging techniques, 
Monte Carlo (MC) codes are useful tools to simulate the complex processes of the ion interactions 
with matter, especially regarding the production of secondary particles. In this work, the calculations 
were performed using the FLUKA MC code.  
FLUKA [6, 7] is a general purpose Monte Carlo code for calculations of particle transport and 
interactions with matter, covering an extended range of applications spanning from proton and 
electron accelerator shielding to target design, calorimetry, activation, dosimetry, detector design, 
Accelerator Driven Systems, cosmic rays, neutrino physics, radiotherapy and others. At energies 
above 100 MeV/n the event generator Relativistic Quantum Molecular Dynamics (RQMD) [8] is used 
to model nuclear interactions. Nuclear interactions of ions below 100 MeV/u are handled by the 
Boltzmann Master Equation (BME) [9] event generator which is still under development but available 
under request. 
2.1 Validation of FLUKA nuclear and electromagnetic models 
For carbon and heavier ions, the FLUKA nuclear and electromagnetic interaction models have been 
validated against experimental data in the whole energy range of relevance for therapy already in [10-
13]. An example is shown in Fig. 1.  
 
Fig. 1: Bragg curve as a function of depth in water for a 400 MeV/u carbon beam. The points [14] 
and the solid line [11] represent the experimental data and the FLUKA calculations, respectively. 
The dose contribution from primary 12C ions and secondary fragments is also reported. Both the 
experimental data and the MC results are normalized by the integralo f the Bragg curve calculated 
between the entrance region and the Bragg peak because the experimental data are obtained as 
relative values.  
Promising comparisons of FLUKA calculations and experimental data for dosimetric and 
radiobiological applications of proton beams were already reported in [15, 16]. In this work a Multi 
Layer Faraday Cup (MLFC) was used for more detailed testing of the relevant interaction models in 
proton therapy. The MLFC is a detector consisting of sheets of two different materials: insulator and 
collector. The MLFC detects only the charge, not dose, of the impinging beam. The longitudinal 
charge distribution along the beam penetration exhibits two distinct regions: a build-up entirely due to 
nuclear reactions and a sharp peak due to primaries stopping by electromagnetic interaction. Thus, this 
method enables a sound separation of the two different interaction processes which are responsible for 
the secondary particle emission and the finite primary ion range, respectively. Previous studies [17, 
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18] were performed to test GEANT3 and GEANT4 nuclear models for 160 MeV protons stopping in 
CH2 (sheets made of polyethylene and brass) and Cu (sheets made of copper and capton). We 
simulated those two experiments with the FLUKA code. The geometry consists of 66 collector sheets 
separated by insulator, the active channels are 64 connected to current integrators, while the collector 
65 is grounded. 
2.2 Ongoing investigation on novel imaging techniques for ion beam therapy 
MC calculations are being currently carried out to investigate the feasibility and to compare the 
performances of particle-based radiographic or tomographic transmission as well as emission imaging 
techniques. The aim of this ongoing work is to identify alternative or complementary methods to 
Positron-Emission-Tomography [19] for possible future application at HIT (Heidelberg Ion Therapy 
Center).  
These novel imaging techiques could be performed using: 
 transmitted high energy primary particles for low dose 2D and 3D imaging to evaluate the 
correct patient positioning and verify the ion range before treatment 
 emerging secondaries [20, 21], in particular protons, from the therapeutic beams to verify 
simultaneously and in-vivo the treatment delivery 
This contribution presents the preliminary results of the Heavy Ion Computed Tomography (HICT). In 
the HICT [22, 23] the distribution of the electron density can be derived directly from the Bethe-Bloch 
formula, measuring the energy or the range loss of the primary beam. This method implies that a small 
ﬂux of ions of higher energy than that used for therapy, is given to the patient before treatment, so that 
the exit energy could be measured. In a first step, we studied the clinical potential of the HICT starting 
from CT data of patients that were treated with carbon ions at GSI (Darmstadt, Germany) during the 
pilot project. We performed the calculations for the WEPL and beam energies needed to achieve the 
HICT for head, prostate and sacral cases, using an own-written MATLAB routine. In addition, the MC 
feasibility of this technique was investigated via MC calculations and compared with the first 
experimental data acquired using standard radiographic films at HIT on the 1st of June 2009. 
The MC feasibility and the measurements for HICT were performed using: 
 12C monoenergetic fields (20  3 cm2) of 400 MeV/u  
 a simple and symmetric PMMA phantom (R = 8 cm) with 5 rods (1 of PMMA, 2 of Air, 1 of 
Lung and 1 of Cortical Bone, r = 1.4 cm) 
 the projections for every 5° from 0° to 180° of the energy loss by 12C ions in the MC 
simulations and the profiles for every 7.5° from 0° to 180° of relative dose on the films   
 a very simple MATLAB-based backprojection algorithm for reconstruction 
3 Results and Discussion 
3.1 Validation of FLUKA nuclear and electromagnetic models 
An example of the validation of the FLUKA nuclear and electromagnetic models against experimental 
data for proton beam using a CH2 MLFC is shown in Fig. 2. A more detailed comparison and 
discussion of the results will be soon reported in a separate paper. In general, from the results obtained 
in this work and the previous benchmarks of other groups we can state that the FLUKA code achieves 
promising and reliable results compared to experimental data for its nuclear and electomagnetic 
models for both protons and carbon ions in the entire energy range of therapeutic interest. 
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Fig. 2: Experiment (circles) and FLUKA MC calculations (lines) in a logarithmic scale 
3.2 Ongoing investigation on novel imaging techniques for ion beam therapy 
Regarding the carbon ion beam energies calculated to evaluate the clinical potential of the HICT for 
head cases we can conclude that the energy values are in a range between 250 and 400 MeV/u, Fig. 3 
(left). So, using the HIT accelerator, that is able to accelerate carbon ions until 430.10 MeV/u, it could 
be possible to performe the HICT for head cases. For the prostate and sacral cases the situation is a 
little bit more complicated. In fact, carbon ion beams of up to 500 MeV/u are needed for the lateral 
beam directions which are normally used for treatment, due to the high density bone structure in the 
beam path. However, it is possible to decrease the energy values by roughly 100 MeV/u via a proper 
reduction of the beam projections trying to skip the bone structures, for example avoiding beam angles 
in the [0°, 25°] interval. An example for a feasible projection with an inclination of  30° is depicted in 
Fig. 3 (right). 
         
Fig. 3: Carbon ion beam energies, displayed in MeV/u in the rainbow color bars, needed to 
perform HICT  for head (left) and prostate (right) cases 
The MC studies for the HICT qualitatively support the feasibility of this method This is shown in the 
left panel of Fig. 4, indicating that the four rods of different material can be clearly distinguished The 
results of the first experiment are shown in the right panel of Fig. 4. With this simple approach using 
standard radiographic films we could only measure relative dose (no energy or range loss) without the 
discrimination of primary and secondary particles which was performed in the MC calculation. Taking 
into account the known limitations of the films as detection system for HICT, as well as the discussed 
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differences between the simulated and experimental quantitities, the reported preliminary results are 
very encouraging and support our current effort for forthcoming experimental investigations with a 
better detection system. 
 
Fig. 4: Qualitative comparison of reconstructed images between MC calculation (left) and 
measurements (right) 
4 Conclusions and Outlook 
Previous works for heavier ions and this further investigation for protons support the reliability of the 
FLUKA nuclear and electromagnetic interaction models for ion therapy applications. In particular, the 
reported results for the MLFC detector indicate improvements of the nuclear models of the current 
standalone FLUKA code version with respect to the old FLUKA-based nuclear models implemented 
in GEANT3 [17]. In addition, the presented MC calculations suggest the feasibility of the HICT if 
properly selecting energy loss deposition of the primary beam and the first preliminary experimental 
investigations simply using standard radiographic films are very encouraging. As a next step, MC 
activities are currently being performed to identify and optimize a more suitable detector system for 
particle radiography and tomography, as well as to address the feasibility of novel in-vivo range 
verification techniques via imaging of prompt particle emission during ion irradiation. 
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